Market Context — Why This Technology, Why Now

The pharmaceutical industry is increasingly focused on drug repurposing and combination therapies to combat rising R&D costs and accelerate market entry. With global oncology spending projected to exceed $250B by 2027, there's immense pressure to deliver effective treatments for underserved patient populations, especially those with drug-resistant cancers. Regulatory bodies are also streamlining pathways for repurposed drugs, further incentivizing this approach. This technology aligns perfectly with these trends, offering a de-risked path to address critical unmet medical needs and capture significant market share.

Key Competitive Advantages
01

Enhances therapeutic efficacy with novel compound action, offering synergistic cancer cell growth inhibition beyond single-agent treatments and providing a new approach for intractable cancers.

02

Secures robust IP protection, having overcome multiple rejections and differentiated from 6 prior art documents, ensuring a stable scope with low invalidation risk for business development.

03

Provides long-term market exclusivity until ~2040, enabling first-mover advantage and competitive superiority to build a sustainable business foundation.

Market Opportunity
Intractable Cancer Treatment 💊
$3B–$3.5B domestically (AI est.)
This technology could expand treatment options for cancer types with limited efficacy from existing therapies, addressing a high market need through a novel mechanism of action.
Oncology pharmaceutical companies Biotech firms specializing in difficult-to-treat cancers Research-focused university spin-offs
Combination Therapy Development 🧪
$5B–$5.5B domestically (AI est.)
Development of combination therapies, aiming for synergistic effects and resistance suppression by combining multiple drugs, is accelerating, and this technology aligns well with this trend.
Large pharmaceutical companies with oncology pipelines Contract research organizations (CROs) for drug development Biotech companies focused on synergistic drug combinations
Drug Repurposing 🔬
$30B–$35B globally (AI est.)
Drug repurposing, which identifies new indications for existing drugs, is a key focus for the pharmaceutical industry due to its potential to significantly reduce development time and costs.
Pharmaceutical companies seeking accelerated drug development Biotech firms specializing in drug discovery platforms Generics manufacturers expanding into novel indications
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a specific pharmaceutical composition for cancer treatment, combining amorolfine, fenticonazole, itraconazole, or their salts with HMG-CoA reductase inhibitors. Its robust claims, refined through multiple rejections and differentiation from six prior art documents, ensure a clear and stable scope with low invalidation risk.

Competitive White Space

White space exists in developing novel drug delivery systems for these compounds or exploring their application in non-oncology indications where HMG-CoA reductase inhibitors or antifungals show therapeutic potential. Further IP could also be built around companion diagnostics for patient stratification.

Economic Impact
~$6.5M/year estimated new revenue per specific cancer market (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming 1,000 patients annually in Japan with a specific cancer type resistant to existing treatments, and an annual drug price of ~$6,500 (AI est.) per patient, this technology could generate ~$6.5M (AI est.) in new annual revenue. Global expansion could significantly increase this market size.

Speed to Market
3× faster than in-house development
The components of this technology are already approved as pharmaceuticals, providing extensive existing data on safety and pharmacokinetics. This could significantly shorten toxicity and early-stage clinical trials compared to developing new compounds, potentially reducing development time by ~3.5 years and enabling faster market entry. Rapid review of non-clinical data and initial clinical trial protocols is feasible.
Competitive Positioning

X: Innovation in Therapeutic Efficacy
Y: Development Risk & Timeline Efficiency

Business Models & Applications
📝 Pharmaceutical Development & Sales Licensing
A business model focused on monetizing the technology through exclusive or non-exclusive licensing for the development, manufacturing, and sales of pharmaceutical compositions.
🤝 Collaborative Research & Development Partnership
Deepen collaboration with Keio University to advance joint R&D, further elucidate the mechanism of action, expand applicable cancer types, and share insights towards commercialization.
🏥 Specialized Pharmaceutical Business for Specific Cancers
Focus on specific intractable cancer types where this technology is particularly effective, launching it as a highly specialized pharmaceutical to target a niche leadership position.
Adjacent Application Opportunities
🔬 Regenerative Medicine & Cell Therapy
Cancer Stem Cell Targeted Therapy
Cancer stem cells resist existing treatments. This technology's compound action could inhibit cancer stem cell proliferation and survival pathways, potentially creating new therapeutic strategies. Combined with regenerative medicine, it could maximize treatment efficacy, addressing a market for advanced cell therapies projected to reach over $50B globally.
🧬 Personalized Medicine & Diagnostics
Companion Diagnostics Integration
Explore biomarkers to identify patient groups most responsive to this technology. Combining it with companion diagnostics could offer more effective, personalized cancer treatments. This synergy with the diagnostics market could tap into a personalized medicine market growing at 10%+ annually.
🍎 Functional Foods & Supplements
Cancer Prevention & Adjunctive Supplements
Certain components of this technology (e.g., HMG-CoA reductase inhibitors), with appropriate dosage and formulation, could be explored for functional foods or supplements aimed at cancer prevention or as adjuncts to existing treatments. This could open new markets contributing to extended healthy lifespans, with the global functional food market exceeding $200B.
Integration Roadmap — Estimated 72-Month Deployment
Phase 1: Basic & Pre-clinical Research
Duration: 9 months
Conduct basic research and animal model pre-clinical trials to thoroughly verify the synergistic mechanism of the technology's components and identify optimal formulation ratios and administration routes.
Phase 2: Clinical Protocol Design & Trial Prep
Duration: 15 months
Design clinical trial protocols based on non-clinical results to evaluate human safety and efficacy. Engage with regulatory authorities and prepare for investigational drug manufacturing and trial execution.
Phase 3: Clinical Trials & Regulatory Approval
Duration: 48 months
Progressively conduct Phase I through Phase III clinical trials to establish robust evidence of the technology's safety and efficacy. Subsequently, submit applications for regulatory approval to achieve market introduction.
Technical Feasibility
The components of this technology have a proven track record as existing pharmaceuticals, allowing initial safety evaluations to potentially be supplemented by existing data. No new compound synthesis is required, and existing pharmaceutical facilities and supply chains can be leveraged, suggesting low technical hurdles in the early development stages. This could enable rapid development initiation and efficient resource allocation.
Success Scenario
Adopting this technology could provide new treatment options for patients with intractable cancers where existing therapies have limited efficacy. This could improve patient quality of life, while enabling the licensee to generate several hundred million dollars in annual revenue within a less competitive niche market (AI est.). Future market expansion through combination with existing treatments is also anticipated.
Patent Record
APPLICATION NO.
特願2020-550447
REGISTRATION NO.
7519682
FILING DATE
2019/10/01
GRANT DATE
2024/07/11
EXPIRATION DATE
2039/10/01
PATENT HOLDER
慶應義塾
Examination History
2021年03月23日
手続補正書（自発・内容）
2022年09月05日
出願審査請求書
2023年08月01日
拒絶理由通知書
2023年09月19日
手続補正書（自発・内容）
2023年09月19日
意見書
2023年12月12日
拒絶理由通知書
2024年01月15日
意見書
2024年01月15日
手続補正書（自発・内容）
2024年03月19日
拒絶理由通知書
2024年04月10日
意見書
2024年06月11日
特許査定